Worldwide Adoption of Ekso Bionics® EksoGT™ Exoskeleton Allows Stroke and Spinal Cord Injury Patients to Take 100 Million ...
December 04 2018 - 9:00AM
More than 240 leading rehabilitation centers in
over 30 countries helped their patients walk 50,000 miles in the
EksoGT exoskeleton during rehab sessions— the distance of walking
around the world twice
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in
exoskeleton technology for medical and industry use, today
announced that the worldwide adoption of the EksoGT™ exoskeleton
has allowed stroke and spinal cord injury patients to take 100
million steps to date (click to tweet). More than 240 leading
rehabilitation centers in over 30 countries helped their patients
walk 50,000 miles in the EksoGT exoskeleton— the distance of
walking around the world twice.
Centers utilizing the EksoGT are advancing both
in-patient and outpatient rehabilitation, and collectively changing
the standard of care to promote better patient outcomes.
As the exoskeleton most widely used in
rehabilitation, the EksoGT:
- is designed to help patients get back on their feet by
supporting re-learning of correct step patterns, weight shifting,
and potentially mitigating compensatory behaviors, enabling
patients to mobilize earlier and restore independence
- is the only exoskeleton with SmartAssistTM software which
provide adaptive amounts of power to either side of a patient’s
body, especially beneficial for stroke patients
- provides the ability to mobilize patients earlier, more
frequently, and with a greater number of high intensity steps
For patients who never thought they would walk
or even stand again, the EksoGT also offers hope.
“Ekso Bionics set out to change the standard of
care in rehabilitation with unparalleled exoskeleton technology,”
said Jack Peurach, CEO and President of Ekso Bionics. “And, thanks
to our Centers of Excellence and other leading rehabilitation
centers, together we were able to achieve the 100 million steps
milestone. These centers are thought leaders and understand how to
use our technology as a tool to improving the lives of their
patients. We are excited to continue to grow the presence of the
EksoGT worldwide so we can continue improving the lives of all of
those who suffer a stroke or spinal cord injury.”
Each year, more than 15 million people
experience a stroke and 500,000 individuals develop a spinal cord
injury worldwide. This cutting-edge exoskeleton technology augments
strength to help patients get back on their feet sooner and walk,
while gaining confidence and freedom. Clinical evidence shows that
including EksoGT gait training during rehabilitation can improve
patient gait speed and walking distance outside of the device at
discharge compared to admission and may improve independence in
functional mobility during inpatient stroke rehabilitation.
“Our Barrow neuro robotics program works to
combine customized robotics with trained functional therapy to
maximize outcomes for neurological patients. The EksoGT is a
significant piece in our neuro robotics program and allows our team
to further customize rehabilitation care,” said Chris St. Clair,
Senior Director of Rehabilitation Services at Dignity Health in
Arizona.
Learn more about innovative centers that are leading the way in
exoskeleton rehabilitation by visiting Ekso Bionics’ Centers of
Excellence.
About EksoGT™EksoGT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. In Europe, the CE-Mark cleared
EksoGTTM allows us to work with patients impacted by all
neurological conditions and lower limb weakness. The EksoGT™ with
SmartAssist™ software is the only exoskeleton available for
rehabilitation institutions that can provide adaptive amounts of
power to either side of a patient’s body, challenging the patient
as they progress through their continuum of care. The suit’s
patented technology provides the ability to mobilize patients
earlier, more frequently, and with a greater number of high
intensity steps. To date, this device has helped patients take 100
million steps in over 240 rehabilitation institutions around the
world.
About Ekso Bionics® Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The company is
headquartered in the Bay Area and is listed on the Nasdaq Capital
Market under the symbol EKSO. For more information,
visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, changes resulting from the Company’s finalization of
its financial statements for and as of the period and year ended
December 31, 2017, information or new changes in facts or
circumstances that may occur prior to the filing of the Company’s
Annual Report on Form 10-K that are required to be included
therein, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:Glenn
Silver646-871-8485eksobionics@lazarpartners.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/48059275-4b5e-4d5d-a9cf-450a67ea1554
A video accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/fa109701-e7eb-46eb-affe-ea86825bf0c6
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024